Patent ID: 11963984
Assignee: UNIVERSITE DE LORRAINE
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A

Claim 0:
1. A method of treating septic shock in a subject in need thereof, comprising administering to said subject thawed human mesenchymal stem cells (MSC) from Wharton's jelly, which were previously cryopreserved at a temperature between a range from −150° C. and −196° C. in a cryoprotectant solution containing at least one cryoprotectant prior to being thawed, said at least one cryoprotectant being selected from the group consisting of dimethyl sulfoxide, glycerol, ethylene glycol, propylene glycol, formamide, butene diol, and combinations thereof,
wherein the expression level of the marker CD44 is at least 10% lower in said thawed human MSC from Wharton's jelly than the expression level of the marker CD44 in fresh human MSC from Wharton's jelly,
wherein said thawed human MSC from Wharton's jelly secrete at least 1.5 times more TGFβ3 than fresh human MSC from Wharton's jelly, and
wherein at least 80% of said thawed human MSC from Wharton's jelly do not express CD34.